Quantum BioPharma Aktie

Quantum BioPharma released Q2 figures for the period ended June 30, 2026: combined cash, cash equivalents and digital assets rose to about USD 9.5 million, shareholders’ equity to USD 6.09 million and working capital to about USD 1.66 million. The current ratio improved to 1.2, while the debt ratio increased to 1.36. Operating and administrative expenses fell significantly. The FDA approved the IND for Lucid‑MS, enabling a Phase 2 trial in patients with progressive multiple sclerosis to begin. » More on de.investing.com

Quantum BioPharma has signed a six-month agreement with IR Agency LLC (Stocks.news) for investor relations and consulting services beginning June 8, 2026. The agency will disseminate company information, create corporate profiles, distribute media content to the financial community, build a digital community and run lead-generation campaigns. The fee is $250,000; the agency is independent and holds no stake in Quantum. Quantum is developing therapies for neurodegenerative and metabolic diseases as well as Lucid-MS for multiple sclerosis; the stock has recently been highly volatile and fell sharply last week. » More on de.investing.com

Quantum BioPharma reports cash and digital assets of $11.3 million, which management says will secure operations through January 2028. Market capitalization is $22.16 million and the Current Ratio is 1.41; however, InvestingPro rates the financial position as "WEAK." Liabilities were reduced from $4.1 million to $2.0 million, operating expenses fell to $15.3 million, and R&D spending dropped to $2.8 million following completion of the Phase‑1 studies. The company completed oral Phase‑1 toxicity studies for Lucid‑21‑302 with no toxic findings, plans an IND filing for Phase‑2 in H1 2026, received a Canadian product license for Qlarity, and a board member resigned. » More on de.investing.com

Quantum BioPharma has appointed Dr. Salvatore Napoli as the principal investigator for the planned phase‑2 study of Lucid‑MS and plans to file an IND with the FDA in the coming weeks. The study will evaluate the efficacy, safety and tolerability of Lucid‑MS in multiple sclerosis; Lucid‑MS is described as a non‑immunomodulatory agent with preclinical activity against demyelination. The stock most recently rose 84% to $4.35, but remains down 73% over six months; the company is valued at $16.65 million and reported a loss per share of $10.10 over the past twelve months. One analysis currently rates the stock above its fair value. » More on de.investing.com

Quantum BioPharma announced the closing of a standalone private placement: 30 Class A shares with multiple voting rights were issued at $25 each, yielding gross proceeds of $750. Insider participation: Xorax Family Trust and Fortius Research each purchased 15 Class A shares and each hold 21 Class A shares after the transaction, representing 50% of the Class A shares and about 37.6% of the voting rights. The company said it will use the funds for general working capital and also settled debts of $260,000 by issuing 17,626 Class B shares at an assumed price of $14.75. Quantum BioPharma was not profitable in the past twelve months and reported a negative EBITDA of $18.64 million. » More on de.investing.com